Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Monday, April 18<br />
Poster Session 8:30 a.m.–7:00 p.m.<br />
P3.153 Acute Peripheral Neuropathy<br />
with Severe Hepatic Dysfunction:<br />
Diagnostic Challenges in Variegate<br />
Porphyria —Doungporn Ruthirago, Parunyou<br />
Julayanont, Sahawat Tantikittichaikul,<br />
Jongyeol Kim<br />
P3.154 The Histopathological<br />
Evaluation of Small Fiber Neuropathy in<br />
Patients with Vitamin B12 Deficiency —<br />
Can Ebru Bekircan-Kurt, Nalan Gunes,<br />
Mehmet Demirci, Sevim Erdem-Ozdamar,<br />
Ersin Tan<br />
P3.155 Castleman’s Disease<br />
Neuropathies —Elie Naddaf, Angela<br />
Dispenzieri, Jayawant Mandrekar, Michelle<br />
Mauermann<br />
P3.156 Polyneuropathy from Wild<br />
Transthyretin Amyloidosis: An Important<br />
New Variety —P. James B. Dyck, Martha<br />
Grogan, Christopher Klein, William Litchy,<br />
JaNean Engelstad, Jenny Davies, Peter Dyck<br />
P3.157 The Francophone Anti-<br />
Mag Cohort: A Clinical Descriptive<br />
Study —Juliette Svahn, Philippe Petiot,<br />
Karine Ferraud, Christophe Vial, Emilien<br />
Delmont, Karine Viala, Jean-Christophe<br />
Antoine, Andoni Echaniz-Laguna, Thierry<br />
Kuntzer, Antoine Gueguen, Jean-Phillippe<br />
Camdessanche<br />
P3.158 When to Suspect Sciatic<br />
Neuropathy: A Chart Review of the<br />
Electrophysiological Findings and Clinical<br />
Etiologies —Adam Aubuchon, Anna<br />
Bracewell, Chad Hoyle, William Arnold, Alan<br />
Sanderson<br />
P3.159 ANCA-Negative Peripheral<br />
Vasculitic Neuropathy Associated with<br />
Minocycline Use —Min Kang, Rajesh Gupta,<br />
Malgorzata Dawiskiba, Michael Pincus,<br />
Jayashri Srinivasan<br />
Clinical Trials in Muscle Diseases<br />
and Healthy Volunteers<br />
P3.160 Effectiveness of<br />
Dichlorphenamide in Periodic Paralysis:<br />
An Observational, Prospective Patient<br />
Registry —Jaya Trivedi, Amanda Jones,<br />
Mark Jasek, Robert Griggs<br />
P3.161 Interim Analysis of a Pilot<br />
Trial of Natalizumab in Inclusion Body<br />
Myositis —David Saperstein, Todd Levine<br />
P3.162 Ataluren: An Overview<br />
of Clinical Trial Results in Nonsense<br />
Mutation Duchenne Muscular<br />
Dystrophy —Craig McDonald, Katharine<br />
Bushby, Mar Tulinius, Richard Finkel, Haluk<br />
Topaloglu, John Day, Kevin Flanigan, Linda<br />
Lowes, Michelle Eagle, Xiaohui Luo, Gary<br />
Elfring, Hans Kroger, Peter Riebling, Tuyen<br />
Ong, Robert Spiegel, Stuart Peltz, Jan<br />
Kirschner<br />
P3.163 ACT DMD: Effect of Ataluren<br />
on Timed Function Tests (TFTs) in<br />
Nonsense Mutation Duchenne Muscular<br />
Dystrophy —Nathalie Goemans, Craig<br />
Campbell, Craig McDonald, Thomas Voit,<br />
Xiaohui Luo, Gary Elfring, Hans Kroger, Peter<br />
Riebling, Tuyen Ong, Robert Spiegel, Stuart<br />
Peltz, Katharine Bushby<br />
P3.164 Safety and Tolerability of<br />
Ataluren in a Phase 3 Study of Patients<br />
with Nonsense Mutation Duchenne<br />
Muscular Dystrophy —Craig Campbell,<br />
Perry Shieh, Thomas Sejersen, Xiaohui Luo,<br />
Gary Elfring, Hans Kroger, Peter Riebling,<br />
Tuyen Ong, Robert Spiegel, Stuart Peltz,<br />
Brenda Wong<br />
P3.165 A Pilot Study to Evaluate<br />
Adherence to the 2010 Care<br />
Considerations for Duchenne Muscular<br />
Dystrophy at Selected Clinics Identified<br />
by the Muscular Dystrophy Surveillance<br />
Tracking and Research Network<br />
(MDSTARnet) Sites. Phase 2: Data from<br />
Medical Record Abstraction —Shree<br />
Pandya, Kristin Caspers Conway, Christina<br />
Trout, Christina Westfield, Deborah Fox<br />
P3.166 ISIS-DMPKRx in Healthy<br />
Volunteers: A Placebo-controlled,<br />
Randomized, Single Ascending-Dose<br />
Phase 1 Study —Laurence Mignon, Daniel<br />
Norris, Kathie Bishop, Frederick Derosier,<br />
ROGER LANE, Frank Bennett<br />
P3.167 Study Design of a Phase<br />
1/2a Trial with ISIS-DMPKRx for the<br />
Treatment of Myotonic Dystrophy Type<br />
1 —Charles Thornton, Richard Moxley, John<br />
Day, Tetsuo Ashizawa, Richard Barohn, Doris<br />
Leung, John Kissel, Nicholas Johnson, Katy<br />
Eichinger, Jason Hardage, Donovan Lott,<br />
Melissa Currence, Nikia Stinson, Wendy King,<br />
Heather Hayes, Frank Bennett, Kathie Bishop,<br />
Laurence Mignon<br />
P3.168 A Pilot Study to Evaluate<br />
Adherence to the 2010 Care<br />
Considerations for Duchenne Muscular<br />
Dystrophy (DMD) at Selected Clinics<br />
Identified by the Muscular Dystrophy<br />
Surveillance Tracking and Research<br />
Network (MD STARnet) Sites. Phase<br />
1:Clinic Director Survey —Shree Pandya,<br />
Kristin Caspers-Conway, Christina Trout,<br />
Christina Westfield, Deborah Fox<br />
Clinical Trials and Treatment of<br />
Myasthenia Gravis<br />
P3.169 A Phase II Trial to Assess the<br />
Efficacy, Safety and Feasibility of 20%<br />
Subcutaneous Immunoglobulin in Patients<br />
with Myasthenia Gravis Exacerbation -<br />
Trial Design —Derrick Blackmore, Ashley<br />
Mallon, Zaeem Siddiqi<br />
P3.170 Therapeutic Target of<br />
Memory B Cells Depletion Helps to Tailor<br />
Administration Frequency of Rituximab<br />
in Myasthenia Gravis —Christine Lebrun<br />
Frenay, Veronique Bourg, Mikael Cohen,<br />
Alexandra Rosenthal, Claude Desnuelle,<br />
Michel Ticchioni<br />
P3.171 INSIGHTS: Analysis of<br />
IVIG Responsiveness in Patients with<br />
Myasthenia Gravis —Todd Levine, Leslie<br />
Vaughn, Gary Badger, Gil Wolfe, Lara Katzin,<br />
David Saperstein, Tahseen Mozaffar, Richard<br />
Barohn, Jonathan Katz, Mazen Dimachkie,<br />
Michelle Greer, Elissa Ritt<br />
P3.172 Effects of Therapeutic Plasma<br />
Exchange on Myasthenic Outcome<br />
Measures —Jeff Guptill, Vern Juel, Janice<br />
Massey, Manisha Chopra, James Howard<br />
P3.173 Methotrexate Polyglutamation<br />
in Myasthenia Gravis —Laura Herbelin,<br />
Mara Becker, Mazen Dimachkie, Jeffrey<br />
Statland, Richard Barohn, Mamatha Pasnoor<br />
P3.174 Susceptibility of Infection in<br />
the Treatment of Myasthenia Gravis —<br />
Harrington Anthony, Mazen Dimachkie,<br />
Jeffrey Statland, Karthika Veerapaneni,<br />
Ahmad Abuzinadah, April McVey, Mamatha<br />
Pasnoor, Melanie Glenn, Omar Jawdat,<br />
Arthur Dick, Dipika Aggarwal, Richard<br />
Barohn, Laura Herbelin<br />
P3.175 A Phase II Trial to Assess<br />
the Efficacy, Safety and Feasibility of<br />
20% Subcutaneous Immunoglobulin<br />
in Patients with Myasthenia Gravis<br />
Exacerbation - Interim Analysis of Safety<br />
and Feasibility —Ashley Mallon, Derrick<br />
Blackmore, Zaeem Siddiqi<br />
P3.176 A Phase II Trial to Assess the<br />
Efficacy, Safety and Feasibility of 20%<br />
Subcutaneous Immunoglobulin in Patients<br />
with Myasthenia Gravis Exacerbation<br />
- Interim Analysis of Efficacy —Zaeem<br />
Siddiqi, Ashley Mallon, Derrick Blackmore<br />
P3.177 Rituximab in "Resistant"<br />
Myasthenia Gravis —Dustin Anderson,<br />
Zaeem Siddiqi<br />
P3.178 Examining Case<br />
Demographics for Myasthenia<br />
Gravis (MG) Comorbidities, to<br />
Compare Plasmapheresis (PLEX) and<br />
Immunoglobulin (IVIg) Treatment<br />
Outcomes in US Hospitals, When<br />
Stratifying by Economic Indicators —Nizar<br />
Souayah, Tamara Opila<br />
Motor Neuron Disease: Clinical<br />
Trials, Treatment, and Outcome<br />
P3.179 Randomized Trial of Low<br />
Expiratory Pressure Non-Invasive<br />
Ventilation for ALS —Teresa Jacobs, Devin<br />
Brown, Veronica Berrocal, Timothy Funckes,<br />
Kirsten Gruis<br />
P3.180 Longitudinal Validation of the<br />
ALS-FTD-Questionnaire - Preliminary<br />
Results —Rosanne Govaarts, Emma<br />
Beeldman, Anita Beelen, Hepke Grupstra,<br />
Anneke Van Der Kooi, Rob De Haan, Ben<br />
Schmand, Joost Raaphorst, Marianne De<br />
Visser<br />
P3.181 Safety, Tolerability and<br />
Monitoring of Long-Term G-CSF<br />
Compassionate Use in ALS Patients —<br />
Siw Johannesen, Andrei Khomenko, Dobri<br />
Baldaranov, Thomas Grimm, Ines Kobor,<br />
Jochen Grassinger, Sabine Klatt, Tina<br />
Kammermaier, Tim-Henrik Bruun, Jan<br />
Kassubek, Gerhard Schuirer, Albert Ludolph,<br />
Wilhelm Schulte-Mattler, Isabeau Prémont-<br />
Schwarz, Armin Schneider, Michael Deppe,<br />
Ulrich Bogdahn<br />
P3.182 Medication Exposure and<br />
Survival in ALS: An Observational Study<br />
Using Inverse Probability of Treatment<br />
Weighting —Nimish Thakore, Erik Pioro<br />
P3.183 Plasmapheresis Improves the<br />
Suppressive Function of Regulatory T<br />
Cells in Patients with Fast-Progressing<br />
Amyotrophic Lateral Sclerosis —Jason<br />
Thonhoff, David Beers, Weihua Zhao,<br />
Shixiang Wen, Jinghong Wang, Luis Lay, Lisa<br />
Thompson, Christopher Leveque, Stanley<br />
Appel<br />
P3.184 Do Abnormal A-Waves Predict<br />
IVIg Responsiveness in Patients with<br />
Motor Neuron Disease Mimic Syndromes?<br />
A Double-Blind Placebo Controlled<br />
Cross-Over Trial —Rahul Remanan, Mona<br />
Shahbazi, Janki Panchal, Lindsay Kaplan,<br />
Shara Holzberg, Dale Lange<br />
P3.185 Survival and Disease<br />
Progression in SOD1 Familial ALS in<br />
North America —Taha Bali, Wade Self,<br />
Teepu Siddique, Leo Wang, Elena Ratti, Kevin<br />
Boylan, Jonathan Glass, Nicholas Maragakis,<br />
James Caress, Steven Scherer, Stanley<br />
Appel, James Wymer, Summer Gibson, Lorne<br />
Zinman, Tahseen Mozaffar, Jennifer Jockel-<br />
Balsarotti, Margaret Allred, Esther Liu, Elena<br />
Fisher, Glenn Lopate, Alan Pestronk, Merit<br />
Cudkowicz, Timothy Miller<br />
P3.186 Decline in Slow Vital Capacity<br />
Predicts Respiratory Insufficiency, Use<br />
of Assisted Ventilation, Tracheostomy or<br />
Death in ALS —Jeremy Shefner, Lisa Meng,<br />
Sarah Kulke, Andrew Wolff, Michael Bozik,<br />
Fady Malik, Jinsy Andrews<br />
P3.187 Predictive Factors of<br />
Survival and Disease Progression After<br />
Gastrostomy Tube Placement in ALS: An<br />
Interim Analysis —Katharine Nicholson,<br />
Kellen Haley, Sarah Cornacchio, Ghazal<br />
Lashgari, Jennifer Scalia, David Schoenfeld,<br />
James Berry, Nazem Atassi<br />
P3.188 A Retrospective Review of<br />
Hematologic and Renal Profiles in Patients<br />
Undergoing Multi-Year Intravenous<br />
Immunoglobulin (IVIg) Therapy for Chronic<br />
Neuromuscular Diseases —Victor Doan,<br />
Said Beydoun<br />
P3.189 A 24-Week, Phase III, Double-<br />
Blind, Parallel-Group Study of Edaravone<br />
(MCI-186) for Treatment of Amyotrophic<br />
Lateral Sclerosis (ALS)—Masahiko Tanaka,<br />
Takeshi Sakata, Joseph Palumbo, Makoto<br />
Akimoto<br />
P3.190 Sustained Efficacy for Up to<br />
12 Months in an Active Extension of a<br />
Phase III Study of Edaravone (MCI-186)<br />
for Treatment of Amyotrophic Lateral<br />
Sclerosis (ALS)—Joseph Palumbo, Takeshi<br />
Sakata, Masahiko Tanaka, Makoto Akimoto<br />
P3.191 A Double-Blind, Parallel-Group,<br />
Placebo-Controlled, 24-Week, Exploratory<br />
Study of Edaravone (MCI-186) for the<br />
Treatment of Advanced Amyotrophic<br />
Lateral Sclerosis (ALS)—Masahiko Tanaka,<br />
Makoto Akimoto, Joseph Palumbo, Takeshi<br />
Sakata<br />
P3.192 A Long-Term Safety and<br />
Efficacy Extension Study of Patients<br />
Diagnosed with Amyotrophic Lateral<br />
Sclerosis (ALS) and Treated with<br />
Edaravone (MCI-186) —Takeshi Sakata,<br />
Joseph Palumbo, Makoto Akimoto, Masahiko<br />
Tanaka<br />
72 2016 AAN Annual Meeting Abstract Listing
Change language